Skip to main content

Pablo Castillo Sánchez

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Pablo Castillo Sánchez

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

Advancing Parkinson's disease management: targeting autophagic-lysosomal dysfunction for innovative diagnostics and therapeutics

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Mercedes Arrúe Gonzalo, Silvia Enriquez Calzada, Jorge Hernández Vara, Pau Sarle Valles, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres, Jordi Riera Heredia, Pablo Castillo Sánchez
Funding agency: Instituto de Salud Carlos III
Funding: 265000
Reference: PI24/00062
Duration: 01/01/2025 - 31/12/2027

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Maria Camprodon Gomez, Pablo Castillo Sánchez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 42000
Reference: 2024 PROD 00073
Duration: 02/12/2024 - 01/06/2026

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson´s and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Jorge Hernández Vara, Maria Camprodon Gomez, Jordi Riera Heredia, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 24440
Reference: CI24-20222
Duration: 01/10/2024 - 30/09/2026

New nanotechnological therapy for Parkinson ?s disease: nose to brain delivery of GBA-polymer nanoconjugates

IP: Marta Martínez Vicente
Collaborators: Pablo Castillo Sánchez, Laia Perez Lasarte
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 73383.97
Reference: AGAUR/FI/2023/CASTILLO
Duration: 01/06/2023 - 31/05/2026

Related news

The nomination recognises the work she has led together with Dr. Núria Peñuelas and Dr. Miquel Vila, on the generation of new preclinical models to study Parkinson's disease.

The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Elena Moreno Parada

Elena Moreno Parada

Tècnic/a Grau Superior
Teaching Unit
Internal Strategy Directorate
Read more
Elena Isabel Crespo Gimeno

Elena Isabel Crespo Gimeno

Main researcher
Nephrology and kidney transplantation
Read more
Soraya Peralta Garzón

Soraya Peralta Garzón

Research technician
Read more
Maria Francesca Eugenia Filippi Arriaga

Maria Francesca Eugenia Filippi Arriaga

Research technician
Clinical Pharmacology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.